Lexaria Nicotine LLC. is the exclusive worldwide provider of the Dehydratech drug delivery technology for the nicotine industry, licensed from our parent Lexaria Bioscience Corp.
Lexaria’s DehydraTECH drug delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of lipophilic molecules such as nicotine.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits upon oral ingestion:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
In animal tests, nicotine measured in blood plasma in as little as 2 minutes.
Initial testing indirectly evidences DehydraTECH™ may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.